Adamax vs Eloralintide
Side-by-side comparison of key properties, dosing, and research.
Cognitive Enhancement
AdamaxGLP-1 / Weight Loss Agonists
Eloralintide- Summary
- Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Half-Life
- Estimated 1-3 hours (short; peptide degradation)
- ~7 days (estimated, long-acting design)
- Admin Route
- Subcutaneous, Intranasal (research)
- SubQ
- Research
- —
- —
- Typical Dose
- 200-400 mcg per dose
- Under investigation in Phase 1/2 trials
- Frequency
- Once daily or every other day
- Once weekly
- Key Benefits
- Proposed enhancement of learning and memory consolidation
- Neuroprotective via BDNF-TrkB pathway support
- May improve mood and resilience to stress
- Potential support for neurogenesis
- Cognitive clarity and focus enhancement (reported anecdotally)
- Explored for neurodegeneration and age-related cognitive decline
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Side Effects
- Limited human safety data; largely anecdotal reports
- Possible headache or mild overstimulation
- Sleep disruption with late-day dosing
- Unknown long-term safety profile
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Stacks With
- —
- —